aTyr Pharma Statistics
Total Valuation
aTyr Pharma has a market cap or net worth of $533.14 million. The enterprise value is $477.34 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
aTyr Pharma has 89.00 million shares outstanding. The number of shares has increased by 33.04% in one year.
| Current Share Class | 89.00M |
| Shares Outstanding | 89.00M |
| Shares Change (YoY) | +33.04% |
| Shares Change (QoQ) | +4.55% |
| Owned by Insiders (%) | 2.27% |
| Owned by Institutions (%) | 70.56% |
| Float | 86.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.87 |
| P/TBV Ratio | 7.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.79, with a Debt / Equity ratio of 0.17.
| Current Ratio | 7.79 |
| Quick Ratio | 7.24 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -79.70% and return on invested capital (ROIC) is -45.00%.
| Return on Equity (ROE) | -79.70% |
| Return on Assets (ROA) | -39.82% |
| Return on Invested Capital (ROIC) | -45.00% |
| Return on Capital Employed (ROCE) | -77.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$975,569 |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +254.44% in the last 52 weeks. The beta is 0.90, so aTyr Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | +254.44% |
| 50-Day Moving Average | 4.73 |
| 200-Day Moving Average | 3.65 |
| Relative Strength Index (RSI) | 67.96 |
| Average Volume (20 Days) | 4,155,259 |
Short Selling Information
The latest short interest is 18.46 million, so 20.75% of the outstanding shares have been sold short.
| Short Interest | 18.46M |
| Short Previous Month | 13.64M |
| Short % of Shares Out | 20.75% |
| Short % of Float | 21.23% |
| Short Ratio (days to cover) | 6.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | -52.82M |
| Operating Income | -67.05M |
| Pretax Income | -53.93M |
| Net Income | -63.41M |
| EBITDA | -66.35M |
| EBIT | -67.05M |
| Earnings Per Share (EPS) | -$0.80 |
Full Income StatementBalance Sheet
The company has $76.35 million in cash and $12.99 million in debt, giving a net cash position of $63.36 million or $0.71 per share.
| Cash & Cash Equivalents | 76.35M |
| Total Debt | 12.99M |
| Net Cash | 63.36M |
| Net Cash Per Share | $0.71 |
| Equity (Book Value) | 74.86M |
| Book Value Per Share | 0.84 |
| Working Capital | 72.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$62.16 million and capital expenditures -$48,000, giving a free cash flow of -$62.21 million.
| Operating Cash Flow | -62.16M |
| Capital Expenditures | -48,000 |
| Free Cash Flow | -62.21M |
| FCF Per Share | -$0.70 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
aTyr Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.04% |
| Shareholder Yield | -33.04% |
| Earnings Yield | -11.73% |
| FCF Yield | -11.50% |
Analyst Forecast
The average price target for aTyr Pharma is $20.20, which is 237.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.20 |
| Price Target Difference | 237.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 363.01% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2019. It was a reverse split with a ratio of 0.0714285:1.
| Last Split Date | Jul 1, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.0714285:1 |
Scores
aTyr Pharma has an Altman Z-Score of -3.89 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.89 |
| Piotroski F-Score | 2 |
